Douglas Love J.D., Esq.
Net Worth

Last updated:

What is Douglas Love J.D., Esq. net worth?

The estimated net worth of Mr. Douglas Love J.D., Esq. is at least $3,729,086 as of 30 Oct 2024. He owns shares worth $429,505 as insider, has earned $460,901 from insider trading and has received compensation worth at least $2,838,680 in Annexon, Inc..

What is the salary of Douglas Love J.D., Esq.?

Mr. Douglas Love J.D., Esq. salary is $709,670 per year as Chief Executive Officer, Pres & Director in Annexon, Inc..

How old is Douglas Love J.D., Esq.?

Mr. Douglas Love J.D., Esq. is 57 years old, born in 1968.

What stocks does Douglas Love J.D., Esq. currently own?

As insider, Mr. Douglas Love J.D., Esq. owns shares in one company:

Company Title Shares Price per share Total value
Annexon, Inc. (ANNX) Chief Executive Officer, Pres & Director 196,121 $2.19 $429,505

What does Annexon, Inc. do?

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX logo
ANNX
Annexon, Inc.
$2.19

Douglas Love J.D., Esq. insider trading

Annexon, Inc.

Mr. Douglas Love J.D., Esq. has made 9 insider trades between 2021-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 78,399 units of ANNX stock on 30 Oct 2024. As of 30 Oct 2024 he still owns at least 196,121 units of ANNX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 78,399 $1.85 $145,038
Option
Stock Option (Right to Buy) 36,050 $1.85 $66,693
Option
Common Stock 36,050 $1.85 $66,693
Sale
Common Stock 5,782 $5.54 $32,032
Sale
Common Stock 6,571 $5.87 $38,565
Purchase
Common Stock 60,000 $2.45 $146,820
Option
Stock Option (Right to Buy) 70,942 $1.41 $100,028
Option
Common Stock 70,942 $1.41 $100,028
Option
Common Stock 30,000 $1.85 $55,500
Option
Stock Option (Right to Buy) 30,000 $1.85 $55,500
Sale
Common Stock 7,500 $22.05 $165,338
Option
Stock Option (Right to Buy) 7,500 $1.41 $10,575
Option
Common Stock 7,500 $1.41 $10,575
Option
Stock Option (Right to Buy) 3,750 $1.41 $5,288
Option
Common Stock 3,750 $1.41 $5,288
Sale
Common Stock 3,750 $1.41 $5,288
Sale
Common Stock 3,750 $1.41 $5,288
Option
Common Stock 3,750 $1.41 $5,288
Option
Stock Option (Right to Buy) 3,750 $1.41 $5,288
Sale
Common Stock 500 $28.1 $14,050
Option
Common Stock 500 $1.41 $705
Option
Stock Option (Right to Buy) 500 $1.41 $705
Option
Common Stock 7,102 $1.41 $10,014
Option
Stock Option (Right to Buy) 7,102 $1.41 $10,014
Sale
Common Stock 7,102 $1.41 $10,014
Sale
Common Stock 3,750 $24.53 $91,980
Option
Common Stock 3,750 $1.41 $5,288
Option
Stock Option (Right to Buy) 3,750 $1.41 $5,288
Option
Common Stock 3,750 $1.41 $5,288
Option
Stock Option (Right to Buy) 3,750 $1.41 $5,288
Sale
Common Stock 3,750 $26.23 $98,348

Annexon key executives

Annexon, Inc. executives and other stock owners filed with the SEC:

  • Dr. Ted Yednock Ph.D. (67) Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
  • Mr. Douglas Love J.D., Esq. (57) Chief Executive Officer, Pres & Director
  • Mr. Michael Overdorf M.B.A. (55) Executive Vice President & Chief Bus. Officer